Peptides for Improving Bone Mass Density
It is accepted that there are many nutritional and lifestyle modifications published which promote their ability to improve oneâ€™s bone mass. However as we age, and the consequences of our lifestyle choices and genetic predispositions present themselves, these therapies lose the ability to offer significant help. It is useful to look into coupling natural treatments with other therapy options, such as peptide supplementation.
Beyond bodybuilding and fat loss, there are peptides researched both in animal and human subjects which are shown to aid in the preservation of bone health. This means that they hold a great potential for reversing symptoms of Osteoporosis.
Osteoporosis is a serious degeneration of the bone tissue resulting in fragility. The development of osteoporosis heightens oneâ€™s risk of experiencing serious falls and bone fractures.
If you are new to the science of peptides, it might be wise to get a quick introduction. Many people are still very close-minded when it comes to advancements in sports medicine and hormonal treatments. Most assume peptides are steroids and only offer anabolic benefits.
The misconceptions in the development and use of peptides have been publicised by media giants for far longer than one would imagine. Especially considering there are years (decades) of reliable research associating peptides and their mechanism of action to numerous health benefits. Our website provides a wealth of information which is designed to educate and set your mind at ease on this type of treatment. You can also refer to the clinical studies referenced to confirm the validity of what is discussed.
1. Growth Hormone (aka GH and Somatotropin)
Growth hormone is that which plays a vital role during childhood and continuing into adulthood, as it is responsible for influencing glucose and lipid metabolism, body composition and bone mineralisation (Bone Mineral Density – BMD).
The Growth Hormone/Insulin-like Growth Factor 1 (GH/IGF1) axis is what determines our final height as children.
GH plays a vital role in the attainment and maintenance of peak bone mass during youth, regardless if the growth has already been completed.
Peak bone mass is the maximum level of bone mass one will have achieved by the end of skeletal maturation. Peak bone mass is looked upon as one of the most significant predictors of bone fracture risk for adults. Peak bone mass is also influenced by diet, physical activity, oneâ€™s weight and existing hormone levels. GH has been shown to accelerate bone turnover, and in vitro studies reveal GH and its primary effector, insulin-like growth factor-1 (IGF-1), are both mitogens for osteoblasts.
Clinical Studies: GH Increases Bone Mass Density
Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis.
Subjects: 29 Men ages 27-62 years old with idiopathic osteoporosis
Objective:Â Investigating the effects of GH treatment on
- Bone Turnover
- Bone Size
- Bone Mineral Density
- Bone Mineral Content
Treatment Duration: 24 months, with a follow-up period of 12 months
- After two yrs: patients were discovered to have an increase in Bone Mass Density in the lumbar spine.Â Bone Mineral Content of the total body and lean body mass had increased, and fat mass decreased in both treatment groups.
- After 36 months:Â Further increases were noted in both groups for Bone Mineral Density and Bone Mineral Content.
- The study concludes that two yrs of intermittent or continuous treatment with GH in males with idiopathic osteoporosis result in an increase in Bone Mineral Density and Bone Mineral Content. This increase is sustained for at least one yr post-treatment.
Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial.
Subjects: 80 osteoporotic, postmenopausal women, 50-70 years of age, with ongoing estrogen therapy (HRT), were randomised to recombinant human growth hormone (GH)
Objective:Â Investigating the effects of GH Treatment for Osteoporosis
Treatment Duration: This study was double-blinded and lasted for 18 months. The placebo group then stopped the injections, but both GH groups continued for a total of 3 years with GH and followed for five years.
- 18 months: Total body bone mineral content was highest in the GH 2.5 U group
- Three years: When the GH treatment was discontinued, total body and femoral neck bone mineral content revealed an increase in both GH-treated groups.
- 4-years: Total body and lumbar spine bone mineral content increased 5% and 14%,
Femoral neck bone mineral density increased 5%
Bone mineral content 13% for GH 2.5 U
- 5-year follow-up: No differences in bone mineral density or bone mineral content
Bone markers showed increased turnover.
Three fractures occurred in the GH 1.0 U group.
Side effects were rare.
- Overall, the bone mineral content showed an increase of 14% with GH treatment. This study indicates there may be a delay that is extended and dose-dependent of the GH on bone health. Researchers conclude that GH supplementation has the potential to be used as an anabolic agent in osteoporosis.